Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
| Autor: | Lebriz Altay, Manuel M. Hermann, Philip Enders, Sascha Fauser, Philipp S. Muether, Vasilena Sitnilska |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Time Factors Angiogenesis Inhibitors Retinal Pigment Epithelium 01 natural sciences chemistry.chemical_compound 0302 clinical medicine Risk Factors Prospective Studies Fluorescein Angiography Aged 80 and over General Medicine Middle Aged Sensory Systems Vascular endothelial growth factor Bevacizumab medicine.anatomical_structure Treatment Outcome Intravitreal Injections Female Tomography Optical Coherence medicine.medical_specialty Fundus Oculi Recombinant Fusion Proteins 03 medical and health sciences Atrophy Ophthalmology Ranibizumab Post-hoc analysis medicine Humans 0101 mathematics Risk factor Aged Retinal pigment epithelium Dose-Response Relationship Drug business.industry 010102 general mathematics Odds ratio Macular degeneration medicine.disease eye diseases Receptors Vascular Endothelial Growth Factor chemistry Concomitant 030221 ophthalmology & optometry Wet Macular Degeneration sense organs business Follow-Up Studies |
| Zdroj: | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 241(3) |
| ISSN: | 1423-0267 |
| Popis: | Purpose: The aim of this study was to evaluate risk factors for the development of retinal pigment epithelium (RPE) atrophy in patients with neovascular age-related macular degeneration (nAMD). Procedures: This post hoc analysis of the prospective RESPONSE study includes 52 therapy-naive nAMD patients without baseline RPE atrophy, who were treated with ≥9 anti-vascular endothelial growth factor (VEGF) injections for ≥3 years. RPE atrophy was assessed via multimodal imaging. Baseline aqueous VEGF and serum complement levels (C3d/C3) were measured. Risk factors for atrophy development were evaluated via logistic regression analysis. Results: Atrophy onset was significantly associated with the duration of nAMD (mean 5.34 years; odds ratio = 1.83, p = 0.012). Anti-VEGF injection number, age, C3d/C3 ratio, baseline intraocular VEGF, or delay to the first treatment had no influence on RPE atrophy. Conclusions: The duration of treatment-requiring nAMD was identified as primary risk factor for the onset of concomitant RPE atrophy after commencing therapy. Targeting concomitant atrophy in nAMD patients might improve the long-term prognosis of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|